Cutaneous T-cell lymphoma: Biologic targets for therapy

Jaehyuk Choi, Francine Foss*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrate stigmata of T-cell activation. As the disease progresses, there appears to be an accumulation of genetic and epigenetic changes that may contribute to the aggressiveness of the disease. Furthermore, the persistence of tumor appears to require escape from cancer immunosurveillance. This process likely requires modulation of the host immune system and skewing of the immune cells away from a cytotoxic phenotype. Each of these steps in disease pathogenesis offers a potential object for targeted therapies. This article reviews the recent research into the design and use of targeted therapies for CTCL.

Original languageEnglish (US)
Pages (from-to)272-277
Number of pages6
JournalCurrent Hematologic Malignancy Reports
Issue number4
StatePublished - Dec 1 2007

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Cutaneous T-cell lymphoma: Biologic targets for therapy'. Together they form a unique fingerprint.

Cite this